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Abstract 
Typhoid fever, which is caused by Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is an 
exclusively human enterically transmitted, range from mild gastroenteritis to severe systemic disease and spread 
by the fecal-oral route via contaminated food and water.In current study done production of polysaccharide 
typhoid vaccine against typhoid fever from local strain (S. Typhi). Identification of S. Typhi (local strain) by 
traditional methods of diagnosis as microscopic examination and biochemical tests as Api20E system diagnosis, 
Vitek-2 and serological test .All confirmed the identity of the bacteria belonging to the Salmonella Typhi. In 
current study, polysaccharide was used as immunogen to production typhoid vaccine from local strain and 
evaluation these vaccine biological, chemical, physical and Immunological with Commercial vaccine and 
comparative the results, the results of biological test as sterility, safety and pyrogenicity test were conforms. A 
result of chemical test (phenol content and residual formalin) by using HPLC and GC, PH value and protein 
content were safety side comparative WHO protocol. On the other hand, the results of physical test present 
particles size of local typhoid vaccine was less than Com. V. the particle, the smaller the particle size of vaccine 
supports the immune response increased immunization. The result Immunological test by ELISA was showed 
that the titration of  PS V. local strain group was high immune response and  significantly differences  (P<0.5) in 
the sera of treated guinea pigs between first and booster dose, control group was Non-significant. The result of 
cellular immune response that present in total white blood corpuscles (WBCs) count  showed no significant 
different of Com. Vaccine and control group between first and booster dose but, there significant different 
(P<0.05) of PS vaccine between first and booster dose. In challenge test the result was showed 80% and 70% 
ratio protected in PS and Com groups vaccines respectively and resisted with the virulent enhance challenge 
exposure against S. Typhi organism after give 100LD50 dose (108) to those animal.In conclusion, can 
reproduction of Iraqi typhoid vaccine (Killed vaccine) that was produced in VIS and stopped since 2003 by using 
new vaccine that recommended by WHO for humane immunization against typhoid fever, also possibility use of 
method evaluation for evaluates commercial typhoid vaccine.      
Keywords: (HPLC) High-performance liquid chromatography, (GC)gas chromatography. 
 
1. Introduction 
Typhoid fever, which is caused by Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is an 
exclusively human enterically transmitted ,range from mild gastroenteritis to severe systemic disease 
(Bnesaru,2015). The extra-intestinal infections caused by Salmonella are very fatal (Marathe,2012). S. Typhi has 
a combination of characteristics that make it an effective pathogen. This species contains an endotoxin typical of 
gram negative organisms, as well as the Vi antigen which is thought to increase virulence (Lillehoj and Okamura, 
2003).  Available vaccine for typhoid fever has less-than-desired efficacy and certain unacceptable side effects, 
making it pertinent to search for new immunogen suitable for vaccine formulation (Sagi, et al., 2006; Hamid and 
Jain, 2008). Al-Shammari et al., (2010) recorded that Vi vaccine in boosting dose after 8 days from vaccination 
is the best efficient and gave highest mean in phagocytosis, Ab titration assay and significant increase in delayed 
hypersensitivity.  World Health Organization in 2008 was recommended that typhoid vaccination be considered 
for the control of endemic disease and outbreaks, but programmatic use remains limited. (Date et al., 2014).  
However, the efficacy of both the vaccines (Ty21a and ViCPS) was approximately (65-70)% (WHO, 2014).  In 
Iraq, typhoid fever was recorded (21,005-22,280) infect among 2013-2014 (Iraq CDC ,2015) , and typhoid 
vaccine (killed Ty21a) was producing till 2003 by Vaccines and Serums Institute / Iraqi Health Ministry as 
1.500.000 dose, divided 500.000 dose for Ministry of Defense and 1.000.000 to Public Health Offices (VSI, 
2015). Now Iraq will depend on importing vaccine to meet the needs, and the development of improved typhoid 
vaccines is a high global public health priority. 
 
2.Methods  
- Bacterial strain  
 Local strain of S. Typhi supplied by the National Center of Drugs Control and Research (NCDCR) /Iraqi 
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Ministry of Health was used in the current study. 
- Identification and Confirmation of local S. Typhi: 
Morphological colonies characteristics were recorded on the media that used for primary identification as blood 
agar, XLD agar and  SS agar of S. typhi  ( Jawetz et al. , 2010). Gram‘s stain was used to examine the isolated 
bacteria for studying the microscopic properties, depending on the color and shape and the presence of a single 
or series (Isenberg and Garcia, 2004). Biochemical Tests according to MacFaddin method (MacFaddin, 2004). 
Serological conformation of local S. Typhi isolate was done according to Koneman  et al., (1992) ,the 
isolate is doing with polyvalent O and H antisera by using slide agglutination test. The tested local strain S. 
Typhi with the 20 biochemical tests and confirmed by API 20E (BioMerieux, France) and confirmed by Vitek-
2(BioMerieux, France).  
- Preparation of Seed Lot, Vi purified lot and vaccine: 
Production of Vi polysaccharide typhoid vaccine (Vi PSTV) shall be based on a seed lot system (WHO, 1994). 
Preparation cells by growing bacteria in group of vials containing 25 ml of brain heart infusion broth at 37 ºC for 
(18-24) hr. The fresh cultures were used to inoculate nutrient agar distribute in culture bottle, 200 ml each this 
bottle. The inoculated bottle was incubated at 37ºC for (18-24) hrs. Then been prepared slides of gram stain of 
each culture bottle to avoid any contamination (Silipo et al., 2002). Phenol 0.05% and heat was used to kill the 
organism modified method WHO, (1994).  After  then  the washing process and sedimentation for the harvest 
using the cooling ultracentrifuge at 13,000 rpm/min  for 10 min. using phosphate buffer solution with every time, 
until get clear solution by use Nalgene bottle, then the extraction and purification of S. Typhi Vi PS (local strain) 
was done according to    WHO, (1994) and  Cui et al., (2010).   
- Biological, Chemical, physical and Immunological tests of Vi PS Vaccines: 
A.  Biological Tests of vaccines: 
- Sterility test: Each final bulk shall be test, Sample of prepared PS , LPS vaccines by cultured on nutrient and 
MacConkey agar for bacterial sterility then incubated at 37ºC for (24-72) hrs., and cultured on Sabouraud 
Dextrose Agar (SDA) then incubated at 25°C for 72 hrs. for mycotic sterility (WHO, 1973 ;Robbins and 
Robbins,1984; Guzman et al., 2006). 
- Safety test or abnormal toxicity: Each final lot were tested  by injection of one human dose into each of two 
guinea pig, weight between  (250-350) g and five mice weight between (17-22) g into i.p. (Wang et al., 2005 ; 
Guzman et al., 2006). 
- Pyrogenicity Test: Modified method of WHO, (1979) was done for a pyrogenicity test using two groups of 
healthy New Zealand white rabbits, each group consist of three rabbits, weighing (2–2.5) kg of each one, by ear 
vein intravenous injection of  0.025µg of  Vi PS typhoid and per ml/kg body weight, a temperature was 
measured each 2hr. post 3hrs. from vaccination by medical thermometer through enter it into the rectal to more 
than half of the thermometer painted after his introduction with paraffin for easy entry and keep the thermometer 
for (3-5) min. , then withdraw it to recorded the temperature (WHO, 1979  ;WHO, 2015) 
B. Chemical test:  
- Molisch's test: A sensitive chemical test for the presence of carbohydrates was done according Admin , (2014);  
Robyt and White, (1987) 
-Protein content: Estimate of total protein in Vi P.S. vaccines with com. vaccines by kjeldahl method to 
certificate purification of vaccines (Pearson, 1970). 
- Phenol content and Residual Formalin: Estimation of the phenol content in the local and LPS vaccines 
by High-performance liquid chromatography (HPLC) and gas chromatography (GC). 
- PH Measure: The PH of each final lot measured by PH meter at (7± 0.5) (WHO, 1994).   
C. Physical test: 
- Inspection of final containers: Inspection of the vial in each final lot and to showing if there are any 
abnormalities as particle. 
- Shaped molecule vaccine: Using Olympus Microscope to determinate particle size in prepared of Vi P.S. 
vaccine. 
D. Immunological test and evaluation Immune Response: 
- Determination dose and Immunogenicity studies: 
 Purified Vi PS V. 25 µg in 0.5 ml was injected as first dose one group of two G. pigs each intramuscular (i.m.) 
into. Group 2 was injected 0.5 ml i.m of PBS as control. Each groups were received a booster dose post 15 days 
from first dose. The challenge  test after 3 weeks from boosting dose. 
- Blood samples collection: At (0, 15 and 30) day from vaccination, 3ml of  blood samples were collected 
from G. pigs via intracardiac puncture , each sample divided into two  portions. First was treated with 
anticoagulant was used for estimated the total WBC count. The second portion left until clotting then 
centrifuged of supernatant to separate the serum and then transferred to suitable plane tube for 
serological tests (Lewis, 2001).  
- Detection of antibody titration in the animal's serum:  
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A.  Evaluation of Humeral Immune Response Titration:  
Estimated titration of humeral immunity in the sera of immunized and control group to G. pigs by enzyme-linked 
immunosorbent assay (ELISA), using the manufacture kit that preparation into university of London / King of 
London College and done those test in Thi-Qar Poison Consultation Center.  
B.  Evaluation of cellular Immune Response: 
Total leukocytes count: Blood samples were collected by heart puncture using a disposable syringe 2ml pre-
coated with heparin. The method was done according to Haen ,(1995) . 
 
2.5. Lethal dose of half animal (LD50) and challenge test 
A. Lethal dose of half animal (LD50): The lethal dose (LD50) of S. Typhi was calculated for challenge, 
according to Reed and Muench, (1938).  S. Typhi grown in nutrient agar and incubated at 37 ºC for (18-24) hrs, 
then preparation the harvest. The culture suspension was serially diluted, each group (10) mice were divided into 
five groups and inject infection dose according McFarland tube (103,104, 105, 106  and 107 ) cfu/ml,  mice were 
injected 0.25 ml/mice of S. Typhi harvest using i.p. route and sterile normal saline NS was injected to control 
group (Venkatesan et al., 2011). All the mices were monitored to check recorded the number survived or dead 
during 15 day period (Robbins and Robbins 1984).  
B. Challenge test: 
The challenge test was conducted after 15 days from the booster dose. The 100 LD50 of S. Typhi were injected 
0.25 ml/G.pig of harvest using i.p. route each vaccinated groups (Vi PS, Com.)  and control group ( that was 
injected PBS). All the mice were monitored to recorded the clinical signs and the number survived or dead 
during 3 days period (Maslog ,1997). 
 
2.6. Statistical Analysis: 
The Statistical Analysis System- SAS (2012) was used to effect of different factors in study parameters. Least 
significant difference-LSD test was used to significant compare between means in the study.  
 
3. Results and Discussion 
3.1. Identification and Confirmation of local strain 
Identification of S. Typhi (local strain) showed that strain was positive result based on the morphological and 
cultural characteristics of the colonies on SS agar, XLD agar and blood agar, as mentioned by  Jawetz et al., 
(2010). 
Microscopic examination of cultures showed the bacteria as mentioned by Muthiadin et al., (2015) 
The results of biochemical tests referred the isolate was S. Typhi as mentioned by MacFaddin, (2004) 
and Jawetz et al., (2010).  
The local isolate that showed conformity with the S. Typhi in slide agglutination test and API 20E test 
showed excellent identification confidence with the S. Typhi organism in Vitek-2 with the identification values 
or probability 99%. 
 
3.2. Result of Biological, Chemical, physical and Immunological tests of local Vaccines  
A. Biological test: 
- Sterility test: The result were confirm the purity of the harvest, free from bacterial and mycotic organisms, and 
there haven’t any contamination, these will as mentioned by  (Robbins and Robbins, 1984; WHO, 1994; Guzman 
et al., 2006). 
-Safety test or Abnormal toxicity: Pathological signs doesn't appear on the animals after 72 hrs. of injection by 
the prepared vaccines that indicate the safety of these vaccines and the animals survived for at least 7 days 
without weight loss, those agree with (Wang et al., 2005 ; Guzman et al., 2006). 
- Pyrogenicity test: The results of pyrogenicity test were as the following table: 
Table (3-1): The results of pyrogenicity of prepared and commercial vaccines. 
 
Type of Vaccine 
Mean ± SE 
Initial temp. (A) Maximum  temp. (B) (B-A) Summation of  (B)-(A) 
PS 38.77 ± 0.62 39.17 ± 0.81 0.40 ± 0.06 0.90 ± 0.07 
Com 38.79 ± 0.80 39.17 ± 0.57 0.38 ± 0.05 0.85 ± 0.087 
LSD value 1.392 NS 1.168 NS 0.120 NS 0.209 NS 
NS: Non-significant. 
There were significant (P<0.05) differences in summation of (B)-(A) between of the purified local Vi 
polysaccharide and Com vaccine. Vaccines safety because its ≤ 1.4 o C (WHO, 2015) and whose safety, 
immunogenicity and efficacy most that the agreement with Fanning, (1997).  
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B. Chemical test: 
- Protein content: According to requirement for Vi PS typhoid vaccine of WHO, 1994 the protein content of 
local and com. Com. vaccine was less than 10 mg per gram of PS, the current result of Vi PS vaccine was 0.50 
mg per gram of PS. These differences in protein content were due to used of different method in extraction and 
purification of PS. The WHO has identified the prescribed percentage of protein and whether the protein was 
less than 10mg per gram increased proportion of them will be considered as contamination in vaccine.  
- Phenol content: The Phenol content in preservative determination by two technique  (HPLC and GC) 
according to WHO, 1994 protocol that should be each single dose content about (0.92-1.25) mg/dose. The result 
of  phenol content by  GC for Com. vaccine  1.20 mg/dose and local typhoid PS vaccine 1.15mg/dose while 
result in HPLC were  Com. vaccine  1.17 mg/dose and local typhoid PS vaccine 1.14 mg/dose respectively. 
Figure (3- 1 and 2). These results were slightly similar as mentioned in WHO protocol in typhoid vaccine (as 
preservative). 
 
Figure (3-1): The result of phenol content in local typhoid vaccine using HPLC technique. 
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Figure (3-3): The phenol content in Com. vaccine by GC. 
 
Figure (3-4): Result of phenol standard by GC. 
- Residual formaldehyde: The Figures (3-5, 6) were showed results of residual formaldehyde content in Com. 
and local typhoid PS  vaccine was < 0.17µg/dose into com. vaccine while free residual from formaldehyde on 
local typhoid PS vaccine, because of company of Com. vaccine using formaldehyde while the current study 
using phenol for killing bacteria to obtained Vi antigen for production local typhoid vaccine. The result agree 
with WHO protocol that safety rate of residual formaldehyde in the vaccine should be ≤100 µg/dose 
(WHO1994). 
 
Figure (3-5): The result of standard Formalin and Phenol comparative with local typhoid PS vaccine by 
GC. 
Gudlavalleti et al.,(2015) mentioned that the ability to accurately measure and report trace amounts of 
residual  formaldehyde impurity in a vaccine product is not only critical in the product release but also a 
regulatory requirement, in many bacterial or viral vaccine manufacturing procedures , formaldehyde is used 
either at a live culture inactivation step or at a protein de-toxification step or at both. 
Although there is no clear guidance limit on HCHO in human vaccines, USFDA has recently 
published a risk assessment on residual formaldehyde in infant vaccines by a remarkable pharmacokinetic 
modeling approach, Mitkus et al., (2013) indicating exogenously applied formaldehyde content (anywhere 
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between (0.4 and 100) µg per 0.5 ml dose) of current infant vaccines is safe. 
Moreover since formaldehyde is not easily ionizable , sensitive techniques such as gas chromatography 
or mass spectrometry could not be applied to micro-analyze this molecule ( Gudlavalleti et al., 2015).  
A reverse phase HPLC method for the determination of low level formaldehyde in a solid drug 
substance was reported by (Soman et al., 2008). 
- PH of vaccine: The PH result to Com. and local Typhoid PS vaccine ranges between 7± 0.5 according as 
mentioned in WHO protocol typhoid vaccine, (1994). pH (acidity and alkalinity) is from the factors affecting 
stability of the vaccines, and used to help the vaccine maintain its effectiveness during storage, vaccine stability 
is essential, particularly where the cold chain is unreliable, therefore instability can cause loss of antigenicity and 
bacterial vaccines can become unstable due to hydrolysis and aggregation of protein and carbohydrate molecules, 
agree with Sun and Köditz, (2012); WHO, ( 2014 ).  
C. Physical test: 
Inspection of final vial: the local typhoid PS vial vaccine in each final lot after closing was a clear, colorless 
liquid and free from visible particles, these results agreed  with requirement WHO of typhoid vaccine. 
(WHO,1994). 
- Shaped molecule vaccine: The determination of shaped molecule vaccine of particle size by Olympus under 
100Xto compare between local typhoid PS vaccine and com. The result showed diffirences in the particale sizes 
between them ,that  all particles were regular shaped in local typhoid PS vaccine, while irregular shaped in com. 
vaccine .Figure (3-8) and Figure (3-9) respectively.  
 
Figure (3-8): Partical size Vi PS. typhoid vaccine under 100X. 
 
Figure (3-9): Partical size of Com. vaccine under 100X. 
These results were due to using high speed centrifugation during extraction of Vi PS that causes 
adherence in particle vaccine with themselves, that’s notice when preparation local vaccine then doing treatment 
by using sonicator. The smaller PS particles used to deliver antigen and the stronger antigen-specific against 
typhoid fever and effective to the same degree as immune adjuvant, Therefore the particles of local vaccine were 
uniform shaped, these mentioned by  (Oyewumi et al. 2010; Joshi et al., 2013). 
D. Result of Immunological test 
1. Slid agglutination test: Slid agglutination test was used by polyvalent sera against antigens of Salmonella, as 
the results showed that the bacteria belonging to the genus S. Typhi gave a positive result for the agglutination 
test react through one min. indicate that positive reaction, as it is characterized by serological diagnosis 
performed easily and speed of the results obtained this agreed with (Collins et al., 1987; Wattiau et al., 2008). 
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2. Evaluation of Immune Response  
A.  Humeral immune response: All immunized groups (5 guinea pigs from each group) were revealed humeral 
response in varied degrees as shown in Table (3-2). Antibody titers between group PS vaccine against S. Typhi 
showed significantly differences (P<0.05), that means of antibodies titers were increased immunized between 
groups and significantly (P<0.05) differences between doses respectively. 
 Then good significant differences (P<0.05) was shown between first and booster dose in the local 
Typhoid PS V. titration as (5520.20 ± 342.13) and (9513.40 ± 881.85) respectively. Figure (3-10) 
Com. vaccine was shown less titration than the local vaccine (Typhoid PS) as (3920.80 ± 3889.78) and 
(5578.40 ± 568.68) in first and booster dose respectively Figure (3-11). Control group that injected PBS haven’t 
immune response (223.20 ± 27.91) and (242.80 ± 48.31) at first and booster dose respectively. Figure (3-12)  
Table (3-2): The result of humeral immune response using ELISA 
 
Groups 
Mean ± SE  
LSD value After  15 days from 1st 
Dose 
After  15 days from 
Booster Dose 
local Typhoid Vi PS V. 5520.20 ± 342.13 9513.40 ± 881.85 1092.48 * 
Com. Typhoid  3920.80 ± 389.78 5578.40 ± 568.68 972.41 * 
Control (PBS) 223.20 ± 27.91 242.80 ± 48.31 32.95 NS 
LSD value 921.84 * 1392.69 * ---- 
* (P<0.05), NS: Non-significant. 
 
 
Figure (3- 10): Antibodies' titration after first and booster dose of Typhoid PS local vaccine. 
 
Figure (3- 11): Antibodies' titration after first and booster dose of Com. Vaccine. 
 
Figure (3- 12): Antibodies' titration after first and booster dose of Control (PBS). 
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When need explanation the current results, it should be know protective antibodies develop within 15 
days after the booster dose PS is a component of the gram-negative eubacterial cell wall which act as a toxin, 
because it’s part of the bacterial cell structure it’s called endotoxin, toxicity is associated with the lipid portion of 
the LPS molecule, although all gram-negative eubacteria have LPS in their cell walls, LPS is not toxic unless its 
released from the outer layer of the cell. When gram-negative bacteria die, their cell walls disintegrate, releasing 
the LPS toxin. Some growing gram-negative bacteria also release LPS toxin due to sloughing or blabbing of 
outer membrane; in these cases, the LPS can have a toxic effects on a host organism (Bates, 2007). 
Result of local typhoid PS and com. vaccine, local typhoid PS was few above immune response 
titration from com. vaccine. This can be because local typhoid PS production from local strain that be stronger 
than from standard strain that used to production com. vaccine, in addition occurred in Iraq seasonal change 
(temperature height in summertime), Al-Karawiy, (2008) host resistance, drug resistance strain and particles size 
of local Typhoid PS vaccine less than the particles size of commercial PS vaccine, the smaller the particle size of 
vaccine may supports the immune response increased immunization. (Joshi et al.,2013). 
3.  Cellular immune response: 
Total white blood cells (WBCs) count: 
Table (3-3) was showed results of G. pigs groups post vaccination after 15 days from first dose were (9.260 ± 
0.82 and 9.050±0.69) cells /mm3. Blood in the Typhoid PS local V., Com. V. respectively. The result showed no 
significant increase in total WBCs count as compared with the control group (6.255± 0.42) cells/ mm3. Blood, 
but the results of guinea pigs groups post vaccination after 15 days from booster dose were (10.200 ± 0.749 and 
9.800±0.79) cells /mm3. Blood in the Typhoid PS local V. and Com. V. respectively, while the control group 
(6.350± 0.51) cells/ mm3. Blood. 
Table (3-3): Total WBCs Cells /mm3. Blood in vaccinated G. pigs post first and booster dose of vaccines. 
uType of VaccineMean 
Type of Vaccine 
Mean of Total WBCs 
Cells /mm3. Blood 
After  15 days from 1st 
Dose 
After  15 days from Booster 
Dose 
LSD value 
PS 9.260 ± 0.82 10.200 ± 0.74 0.866 * 
Com 9.050 ± 0.69 9.800 ± 0.79 0.891 NS 
Control 6.255 ± 0.42 6.350 ± 0.51 0.503 NS 
LSD value 1.6628 * 2.1755 * ---- 
* (P<0.05), NS: Non-significant. 
The result showed no significant different in total WBC count of Com. Vaccine and control group 
between first and booster dose. Each groups of vaccines in first dose or booster dose have significant different 
(P<0.05). LPS can trigger the complement cascade by the alternative pathway, endotoxin interacts with the blood 
clotting system and gave physiological effectiveness may result in the inappropriate clotting of blood in the 
peripheral vasculature, Rietschel and Brade, (1992). In addition WBC are considered as the active cells in 
starting out the functions of the immune system, both non-specifically and specifically, and their count may give 
a general picture about the function of the immune system (Lydyard and Grossi, 1998). Due to these diverse 
immunological functions, the normal counts of WBC total can be deviated by infections (Ad’hiah et al., 2002). 
In agreement with such them, both counts total of leukocytes were deviated in the present study. In a more recent 
estimation, the range was (5000-12000) cells/ mm3.blood (McGarry et al., 2010). 
The Table (3-3) was showed of counts of WBC total at first dose were less than from booster dose of 
vaccines after collection blood from vaccines group primed with PS the total WBCs counts was significantly 
(P<0.05) increased as compared with control  and Com. group, Com. V. group (9.800± 0.79 cells/ mm3. blood) 
and  control group (6.350± 0.51 cells/ mm3. blood);  an observation that may suggest that Typhoid local Vaccine 
may able to enhance the adaptive immunity. Such suggestion has some support from a study carried out by 
( Mahieu et al., 2006; Dejager et al., 2010 ;  AL- Shibbani  and Alkhozai , 2015). 
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3.3. Result of lethal dose of half animal (LD50) and challenge test: 
The result of LD50 of S. Typhi was 106 CFU/ml as shown in Table (3-4). 
Table (3-4): The results of lethal dose (LD50) for S. Typhi 
 
Dilutions of 
S. Typhi 
culture (103-
107) cfu/ml 
 
No. of mice 
per group 
 
Injected 
Volume 
(i.p.) per 
ml 
No. of  live and death 
during 15 days period 
of observation 
 
Cumulative 
numbers 
   
 
mortality 
 
% 
  
Live 
 
Dead 
 
live 
 
dead 
103 10 0. 25 10 - 2 8 80 
104 10 0. 25 8 2 6 14 70 
105 10 0. 25 6 4 12 18 60 
106 10 0. 25 4 6 20 20 50 
107 10 0. 25 2 8 30 20 40 
Control*  10 0. 25 10 - - - - 
LSD value --- --- 12.794 ** 12.794 ** --- --- 9.316 ** 
Control*: Normal Saline.    ** (P<0.01) 
Post 15 days from booster dose of vaccines, the challenge dose was 100LD50 (108 CFU/ml) that was 
injected intra-peritoneally into G. pigs groups (vaccination and control groups) as the following table: 
 Table (3-5): The results of challenge test for local prepared and com. vaccines in G. pigs. 
 
 
Groups 
 
No. of animal 
challenged  (i.p) per 
0.25 ml 
No. of  survival to challenged 
and infected /death during 3 
days period of observation 
 
  
survival % 
survival Death 
Vi PS 10 8 2 80 
COM 10 7 3 70 
Control  10 0 10 0 
Chi-square --- -- -- 14.072 ** 
** (P<0.01) 
The result were showed 80% and 70% ratio protected in PS and Com groups respectively and resisted 
with the virulent challenge exposure against S. Typhi organism but G. pigs of unvaccinated control group were 
recorded as dead which was similar to Mastroeni et al., (1993); Venkatesan et al., (2011). 
Control group showed depression, loss of appetite, severe diarrhea, and positive feacal culture. Before 
death they showed signs of dehydration, recumbence with shallow respiration and weak pulse. Death occurs 
within (3) days post challenge as the Table (3-5). Animals of the two groups survived the challenge exposure, 
and only during the first week post challenge the feacal cultures were positive to S. Typhi. 
Animals of the four groups that survived the challenge exposure were slightly depressed with normal 
appetite and normal feaces, and only during the first week post challenge the feacal cultures were positive to S. 
Typhi. 
- Conclusions: The possibility of using PS Typhoid Vaccine from local strain as vaccine against typhoid fever 
increasing the immunization ability more than commercial vaccine. We can reproduction of Iraqi typhoid 
vaccine (Killed vaccine) that was produced in VSI and stopped since 2003 by using new vaccine that 
recommended by WHO for humane immunization of typhoid fever. 
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